Merck/Kelun ADC Combination Beats Keytruda in First-Line Lung Cancer Trial

By FieldPulse Staff · May 23, 2026

Tags: clinical trials, launch, strategy, oncology

Merck and Kelun reported first-line lung cancer data showing their ADC combination outperformed Keytruda on progression-free survival in the study population.

Merck and Kelun reported first-line lung cancer trial data showing their ADC combination outperformed Keytruda on progression-free survival in the study population.

The result is notable because it places a newer ADC-based approach directly against one of the most important benchmarks in oncology.

The business significance is straightforward: strong first-line lung cancer data could strengthen Merck's next-wave oncology positioning and intensify competition in a high-value treatment setting.